Novavax announced Thursday that its COVID-19 infectious-disease proved safe and effective in a study of 12- to 17-year-olds.
Novavax makes a protein-based vaccine — a different type than the most widely used shots — that’s a late arrival in the COVID-19 arsenal.
MASK MANDATES EASED ACROSS US AS COVID-19 HOSPITALIZATIONS DROP BELOW 100,000
Its shots have been cleared for use in adults by regulators in Britain, Europe and elsewhere and by the World Health Organization, and are under review by the U.S. Food and Drug Administration.
A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George’s University hospital in London.
FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration. REUTERS/Dado Ruvic/File Photo
Armed with the new data, Novavax plans to soon seek expanded use of its shots down to age 12. Later this year, it plans to begin testing in younger children.
The latest study enrolled 2,247 U.S. kids ages 12 to 17 last summer and found the two-dose vaccine was 80% effective at preventing symptomatic COVID-19 infection.
FAUCI SAYS ‘FULL-BLOWN’ COVID-19 PANDEMIC IS ALMOST OVER IN US
That was when the extra-contagious delta variant was circulating. The company said six vaccine recipients developed mild COVID-19 compared to 14 kids who received dummy shots. There were no serious infections.
Person receives his second Novavax injection from Dr. Tia Babu to fight against COVID-19.
(Getty Images)
In June, Maryland-based Novavax announced its vaccine was about 90% effective against symptomatic infectious-diseasein a study of nearly 30,000 people in the U.S. and world-regions. More recently, it has cited laboratory data suggesting the vaccine offers some protection against the more contagious omicron variant, although a booster worked better.
CLICK HERE TO GET THE FOX NEWS APP
The Novavax vaccine is made with lab-grown copies of the spike protein that coats the coronavirus, mixed with an immune-boosting chemical. That’s similar to shots used for years against other diseases such as hepatitis B. It’s a different technology than the Pfizer and Moderna options that deliver genetic instructions for the body to make its own spike protein.
